Gemcitabine (Jewel) has small clinical benefits in pancreatic ductal adenocarcinoma (PDAC). EMAP (10 μM) was 35 22 81 and 6 percent; mix of gemcitabine with bevacizumab EMAP or sunitinib had zero additive results. In endothelial HUVECs gemcitabine bevacizumab sunitinib and EMAP triggered 70 41 86 and 67 percent inhibition while mix of gemcitabine with bevacizumab… Continue reading Gemcitabine (Jewel) has small clinical benefits in pancreatic ductal adenocarcinoma (PDAC).